Predicting response to immune checkpoint inhibitor plus chemotherapy in EGFR-mutant lung adenocarcinoma following first-generation TKI resistance: a multicenter deep learning study.

Abstract excerpt

Background: Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma who develop resistance to first-generation tyrosine kinase inhibitors (TKIs) without a T790M mutation face a therapeutic dilemma with limited and suboptimal options. Methods: In this multicenter retrospective study, the final analyzable modeling cohort included 490 patients with complete eligible CT imaging and outcome...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenocarcinoma of Lung
• Share to Antineoplastic Combined Chemotherapy Protocols